about
The prolyl-isomerase Pin1 is a Notch1 target that enhances Notch1 activation in cancerMitf regulation of Dia1 controls melanoma proliferation and invasivenessGenomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumorsQuantification of HER family receptors in breast cancerSmall Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway OncogenesNUMB controls p53 tumour suppressor activityOncogene-induced senescence is a DNA damage response triggered by DNA hyper-replicationAn atlas of altered expression of deubiquitinating enzymes in human cancerFrequent alterations in the expression of serine/threonine kinases in human cancers.Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.Pirin inhibits cellular senescence in melanocytic cells.Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity.PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies.MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.The fragile X protein binds mRNAs involved in cancer progression and modulates metastasis formation.PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancerRNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies.Monoclonal antibodies against the human somatostatin receptor subtypes 1-5: development and immunohistochemical application in neuroendocrine tumors.Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO TrialTankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer.Chromosomal rearrangements in acute myeloid leukemia (AML).A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status.The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium.Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.Prep1 (pKnox1)-deficiency leads to spontaneous tumor development in mice and accelerates EmuMyc lymphomagenesis: a tumor suppressor role for Prep1.Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencingPrediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay.High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma.ERRATUM: Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity.Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.Contrasting roles of SPARC-related granuloma in bacterial containment and in the induction of anti-Salmonella typhimurium immunity.Survival prediction of stage I lung adenocarcinomas by expression of 10 genes
P50
Q24317638-DDE51538-304F-4ABB-B6E7-019488C17ECFQ24672631-9D0B55E2-37B7-44A6-BBEE-4462C2A67971Q26998790-2777CCCE-0390-4178-9471-C1273AB34E61Q27015506-8821C0E1-A3C0-460A-BFD9-DBF0E5696086Q28115989-09BB8560-5033-40BB-B722-DD329D03176AQ28263413-A05FFAB5-097A-4438-A33F-B4A2DF428D8BQ29617915-D3EEDB56-A819-46BA-B912-47F652C5759CQ33808690-D5730EB6-D8E1-46F2-83C7-9B601A05ADB6Q33998589-EBDBD61D-A5BA-4E3E-B53D-B72EE2F01405Q34736064-28A08714-1510-4CC5-9F0F-C397E904135DQ34838382-DCA94D5B-01A6-45FD-9942-A0BEEFF0F818Q35079683-CBEAB976-4562-4CA4-A674-54183937047CQ35562967-F23C26F0-9532-4C73-AA1C-B926C8CA3181Q35663687-5AA2C048-3219-42E3-85C9-309318CBDE1BQ36545717-9B8E4090-26F1-4053-AA04-58210A73AEFFQ37142882-C26E2BAC-1025-4E5C-AEA2-DA3579001C4CQ37237119-904CC390-3C13-4B99-B203-54967E5AFD2FQ37380424-798D0899-CBEB-4A81-A09C-4BA622DF12EEQ37381179-A7A58A7B-849A-47EE-ADD2-45A12893ED11Q37636623-D5256B10-1118-40B1-B9DE-500790553D53Q38387030-DEE4827E-AD79-490F-B969-219709FC8908Q38390966-37317E9F-2E2A-4655-9808-7E04E2D729EDQ38394353-61AC90C8-148F-4592-AE35-290685F042CEQ38406569-9F3398D5-7B29-4D01-8109-B04E89BC7838Q38407917-ED3EF33F-C717-403E-AD74-5CE3BC18D126Q38847936-78BB13A5-11E5-4269-B515-DAD1AA430FDFQ38860960-56611958-2097-4F43-82AC-A6070AD26745Q39689357-431C5D36-0653-4194-BFB8-5F9B748973C3Q39802879-097EE7BC-BC91-44BE-8D8F-38DC03DEF2DAQ40012147-EE21A946-C176-407B-80DF-7FC545B23F5DQ40710007-4DC1685D-D4B1-46A0-B76F-425DEF100D19Q41130333-6EC01628-5BE2-4371-8F49-B07FAE125B59Q41134756-49C789EE-4738-485C-A975-69158B151A1CQ41604830-88837435-33B3-4F7D-A86B-B3ADE14B9900Q41735415-D96342EE-F89C-4C4F-A511-85AF45F31823Q42444949-96A9DD2E-DEBC-4105-B478-13776A226450Q42472757-B3CBDC4B-71E7-4361-9EDD-518B58911F07Q42506362-48B75A52-42A8-436F-A157-8061E9394C5CQ42576505-36DFEC00-8FCE-4250-B0E9-32077D9EBB2CQ42585784-5F2A6DE5-A9FE-4B93-ABE3-BAF14707FC90
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Paolo Nuciforo
@ast
Paolo Nuciforo
@en
Paolo Nuciforo
@es
Paolo Nuciforo
@nl
Paolo Nuciforo
@sl
type
label
Paolo Nuciforo
@ast
Paolo Nuciforo
@en
Paolo Nuciforo
@es
Paolo Nuciforo
@nl
Paolo Nuciforo
@sl
prefLabel
Paolo Nuciforo
@ast
Paolo Nuciforo
@en
Paolo Nuciforo
@es
Paolo Nuciforo
@nl
Paolo Nuciforo
@sl
P106
P21
P31
P3835
paolo-nuciforo
P496
0000-0003-1380-0990